Clopidogrel prescribing and concordance with the pharmaceutical benefits scheme in hospital patients

Marianne Luinstra, Mark Naunton, Gregory M. Peterson, Luke R. Bereznicki

Research output: Contribution to journalArticle

Abstract

Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine clopidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals. Clopidogrel prescribing was examined and the indication for discharge on clopidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54% of patients from the Royal Darwin Hospital and 39% of patients from the Royal Hobart Hospital discharged on clopidogrel met PBS criteria. The main reason for noncompliance with the PBS was absence of a history of cardiovascular or cerebrovascular events while on low-dose aspirin and an absence of contraindications to aspirin at the time of clopidogrel prescribing. Conclusion: Although clopidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.

Original languageEnglish
Pages (from-to)265-268
Number of pages4
JournalJournal of Pharmacy Practice and Research
Volume39
Issue number4
DOIs
Publication statusPublished - 1 Jan 2009
Externally publishedYes

Fingerprint

clopidogrel
Pharmaceutical Preparations
Aspirin

Cite this

Luinstra, Marianne ; Naunton, Mark ; Peterson, Gregory M. ; Bereznicki, Luke R. / Clopidogrel prescribing and concordance with the pharmaceutical benefits scheme in hospital patients. In: Journal of Pharmacy Practice and Research. 2009 ; Vol. 39, No. 4. pp. 265-268.
@article{6845b4b15ccc4fd7ac2af4ba28abf485,
title = "Clopidogrel prescribing and concordance with the pharmaceutical benefits scheme in hospital patients",
abstract = "Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine clopidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals. Clopidogrel prescribing was examined and the indication for discharge on clopidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54{\%} of patients from the Royal Darwin Hospital and 39{\%} of patients from the Royal Hobart Hospital discharged on clopidogrel met PBS criteria. The main reason for noncompliance with the PBS was absence of a history of cardiovascular or cerebrovascular events while on low-dose aspirin and an absence of contraindications to aspirin at the time of clopidogrel prescribing. Conclusion: Although clopidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.",
author = "Marianne Luinstra and Mark Naunton and Peterson, {Gregory M.} and Bereznicki, {Luke R.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1002/j.2055-2335.2009.tb00471.x",
language = "English",
volume = "39",
pages = "265--268",
journal = "Australian Journal of Hospital Pharmacy",
issn = "0310-6810",
publisher = "Wiley-Blackwell",
number = "4",

}

Clopidogrel prescribing and concordance with the pharmaceutical benefits scheme in hospital patients. / Luinstra, Marianne; Naunton, Mark; Peterson, Gregory M.; Bereznicki, Luke R.

In: Journal of Pharmacy Practice and Research, Vol. 39, No. 4, 01.01.2009, p. 265-268.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clopidogrel prescribing and concordance with the pharmaceutical benefits scheme in hospital patients

AU - Luinstra, Marianne

AU - Naunton, Mark

AU - Peterson, Gregory M.

AU - Bereznicki, Luke R.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine clopidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals. Clopidogrel prescribing was examined and the indication for discharge on clopidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54% of patients from the Royal Darwin Hospital and 39% of patients from the Royal Hobart Hospital discharged on clopidogrel met PBS criteria. The main reason for noncompliance with the PBS was absence of a history of cardiovascular or cerebrovascular events while on low-dose aspirin and an absence of contraindications to aspirin at the time of clopidogrel prescribing. Conclusion: Although clopidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.

AB - Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine clopidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals. Clopidogrel prescribing was examined and the indication for discharge on clopidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54% of patients from the Royal Darwin Hospital and 39% of patients from the Royal Hobart Hospital discharged on clopidogrel met PBS criteria. The main reason for noncompliance with the PBS was absence of a history of cardiovascular or cerebrovascular events while on low-dose aspirin and an absence of contraindications to aspirin at the time of clopidogrel prescribing. Conclusion: Although clopidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.

UR - http://www.scopus.com/inward/record.url?scp=75649083051&partnerID=8YFLogxK

U2 - 10.1002/j.2055-2335.2009.tb00471.x

DO - 10.1002/j.2055-2335.2009.tb00471.x

M3 - Article

VL - 39

SP - 265

EP - 268

JO - Australian Journal of Hospital Pharmacy

JF - Australian Journal of Hospital Pharmacy

SN - 0310-6810

IS - 4

ER -